Our Story
Archimedic is Where MedTech Lives
Our Journey to an Integrated MedTech Approach
Archimedic traces its origins to 2009, with the founding of Boston Device Development, Inc. by Eric Sugalski in Boston, MA. Since then, the company has evolved through growth, rebranding (Boston Device Development → Smithwise → Archimedic), strategic mergers, and a move to the Philadelphia area.
While much has changed over time, one thing has remained constant: a commitment to improving patient lives by helping innovators bring meaningful medical technologies to market.
Â
Learning What Makes Devices Succeed
As our team gained experience across a wide range of medical device programs, we developed a deeper understanding of what truly drives success. It became clear that bringing a device to market requires more than strong design — it depends on effectively navigating three distinct, yet interconnected, workflows: design, regulatory, and go-to-market.
When these areas operate in silos, even the most promising innovations can stall. But when they are aligned from the start, development becomes more efficient, risks are reduced, and outcomes improve.
This insight led to the development of our integrated Design + Regulatory + Go-to-Market (DRG) framework — a structured approach that helps “unlock” device concepts and guide them from early ideation through approval and adoption. Over the past several years, we’ve applied this model across more than 50 clients and 100+ medical device programs.
Â
Built Through Change, Focused on Impact
The MedTech landscape has continued to evolve, with recent years bringing new challenges across funding, regulatory expectations, and market dynamics. Through these shifts, Archimedic has remained committed to its mission and approach — adapting where needed while staying grounded in the principles that drive successful device development.
Today, Archimedic supports innovators at every stage, combining engineering, regulatory expertise, and go-to-market strategy to help bring devices from concept to real-world impact. We’re proud of how far we’ve come — and even more excited about what’s ahead for the innovators and patients we serve.
Â